Daniel J. Cohen

Paris, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 19 publications

Quantifying cell cycle regulation by tissue crowding.

Quantifying cell cycle regulation by tissue crowding.

Journal: Biophysical journal

Published: February 22, 2024

Combinational Drug Repurposing from Genetic Networks Applied to Alzheimer's Disease.

Combinational Drug Repurposing from Genetic Networks Applied to Alzheimer's Disease.

Journal: Journal of Alzheimer's disease : JAD

Published: July 11, 2022

Trust in scientists in times of pandemic: Panel evidence from 12 countries.

Trust in scientists in times of pandemic: Panel evidence from 12 countries.

Journal: Proceedings of the National Academy of Sciences of the United States of America

Published: August 09, 2021

Network bioinformatics analysis provides insight into drug repurposing for COVID-19.

Network bioinformatics analysis provides insight into drug repurposing for COVID-19.

Journal: Medicine in drug discovery

Published: January 26, 2021

Combination of acamprosate and baclofen (PXT864) as a potential new therapy for amyotrophic lateral sclerosis.

Combination of acamprosate and baclofen (PXT864) as a potential new therapy for amyotrophic lateral sclerosis.

Journal: Journal of neuroscience research

Published: February 12, 2020

Synergistic PXT3003 therapy uncouples neuromuscular function from dysmyelination in male Charcot-Marie-Tooth disease type 1A (CMT1A) rats.

Synergistic PXT3003 therapy uncouples neuromuscular function from dysmyelination in male Charcot-Marie-Tooth disease type 1A (CMT1A) rats.

Journal: Journal of neuroscience research

Published: February 05, 2020

Next-generation drug repurposing using human genetics and network biology.

Next-generation drug repurposing using human genetics and network biology.

Journal: Current opinion in pharmacology

Published: November 28, 2019

Early short-term PXT3003 combinational therapy delays disease onset in a transgenic rat model of Charcot-Marie-Tooth disease 1A (CMT1A).

Early short-term PXT3003 combinational therapy delays disease onset in a transgenic rat model of Charcot-Marie-Tooth disease 1A (CMT1A).

Journal: PloS one

Published: June 15, 2018

Skin Biopsy Findings in Patients With CMT1A: Baseline Data From the CLN-PXT3003-01 Study Provide New Insights Into the Pathophysiology of the Disorder.

Skin Biopsy Findings in Patients With CMT1A: Baseline Data From the CLN-PXT3003-01 Study Provide New Insights Into the Pathophysiology of the Disorder.

Journal: Journal of neuropathology and experimental neurology

Published: February 07, 2018

Paraganglioma of the bladder in a kidney transplant recipient: A case report.

Paraganglioma of the bladder in a kidney transplant recipient: A case report.

Journal: Molecular and clinical oncology

Published: November 03, 2016

A Rasch Analysis of the Charcot-Marie-Tooth Neuropathy Score (CMTNS) in a Cohort of Charcot-Marie-Tooth Type 1A Patients.

A Rasch Analysis of the Charcot-Marie-Tooth Neuropathy Score (CMTNS) in a Cohort of Charcot-Marie-Tooth Type 1A Patients.

Journal: PloS one

Published: September 29, 2016

Erratum to: An exploratory randomised double-blind and placebo-controlled phase 2 study of a combination of baclofen, naltrexone and sorbitol (PXT3003) in patients with Charcot-Marie-Tooth disease type 1A.

Erratum to: An exploratory randomised double-blind and placebo-controlled phase 2 study of a combination of baclofen, naltrexone and sorbitol (PXT3003) in patients with Charcot-Marie-Tooth disease type 1A.

Journal: Orphanet journal of rare diseases

Published: May 16, 2016

Showing 1-12 of 19

Last Updated: 09/26/2026